Bayer (ETR:BAYN) Rating Reaffirmed
The financial company has just set a target price per share of EUR 134.00 on Bayer (ETR:BAYN) shares. This is 17.44% from the last price. In an analyst note distributed to Clients on Thursday, 10 December, equinet AG has decided to reaffirm their “Neutral” rating on shares of BAYN.
From a total of 18 analysts covering Bayer (ETR:BAYN) stock, 9 rate it a ”Buy”, 0 a “Sell”, and 9 a ”Hold”. This means that 50% of the ratings are positive. The highest target price is €160 while the lowest target price is €121. The mean of all analyst targets is €141.91 with a 24.92% above today’s (€113.6) stock price. Bayer was the topic of 52 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. Jefferies maintained shares on December 8 with “Hold” rating. Bernstein upgraded shares to “Outperform” rating and €152 target share price in a report from a November 13. Deutsche Bank upgraded BAYN stock in a recent report from December 1 to “Buy” rating. Commerzbank maintained the rating on November 7. Commerzbank has a “Hold” rating and a €121 price target on shares. Finally, Credit Suisse upgraded the stock to “Outperform” rating in a report issued on a November 17.
The stock decreased 2.07% or EUR 2.4 on December 9, striking EUR 113.6. Approximately 4.07 million shares of stock traded hands or 129.94% up from the average. Bayer AG (ETR:BAYN) has 0.00% since May 13, 2015 and is . It has outperformed by 0.80% the S&P500.
Bayer AG is a strategic management holding company. The company has a market cap of 95.97 billion EUR. The Company’s business are organized into three subgroups: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. It has 25.79 P/E ratio. Bayer HealthCare researches, develops, makes and markets products to improve the health of people and animals.